Menu Search
Equities

Elliptic Laboratories ASA

ELABS:OSL

Elliptic Laboratories ASA

Actions
TechnologyTechnology
  • Price (NOK)10.26
  • Today's Change-0.24 / -2.29%
  • Shares traded127.42k
  • 1 Year change-40.42%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in NOK

The one analyst offering a 12 month price target expects Elliptic Laboratories ASA share price to rise to 22.00 in the next year from the last price of 10.26.
High114.4%22.00
Med114.4%22.00
Low114.4%22.00

Earnings history & estimates in NOK

On Jul 11, 2024, Elliptic Laboratories ASA reported 2nd quarter 2024 earnings of 0.04 per share. This result was in line with the expectation of the one analyst following the company and was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Nov 21, 2024.
Average growth rate-40.98%
Elliptic Laboratories ASA reported annual 2023 losses of -0.36 per share on Feb 15, 2024.
Average growth rate-98.97%
More ▼

Revenue history & estimates in NOK

Elliptic Laboratories ASA had 2nd quarter 2024 revenues of 33.88m. This missed the 41.00m estimate of the one analyst following the company. This was 736.64% above the prior year's 2nd quarter results.
Average growth rate+23.43%
Elliptic Laboratories ASA had revenues for the full year 2023 of 69.63m. This was 33.75% above the prior year's results.
Average growth rate+8.17%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.